权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Chemical Genetic Analysis of the Human Cell Cycle

人类细胞周期的化学遗传分析

基本信息

批准号：
9128664
负责人：
ROBERT P FISHER
金额：
$ 32.07万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-09-01 至 2018-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9128664
关键词：
Ablation Active Sites Alleles Antineoplastic Agents Apoptosis Benefits and Risks Binding Binding Sites Biological Process Cell Cycle Cell Cycle Regulation Cell Fraction Cell Proliferation Cell Proliferation Regulation Cell division Cells Cessation of life Checkpoint kinase 1 Colon Carcinoma Complement Complex Coupled Cyclin-Dependent Kinase Inhibitor Cyclin-Dependent Kinases Cyclins DNA Damage DNA Double Strand Break DNA biosynthesis Development Discrimination Dissection Ensure Enzymes Event Family Feedback Financial compensation Gene Expression Genes Genetic Techniques Goals Growth and Development function Health Human Human Engineering Individual Ionizing radiation Logic Malignant Neoplasms Mammalian Cell Mitogens Mus Mutate Mutation Nijmegen Breakage Syndrome Normal tissue morphology Organism Pathway interactions Phosphotransferases Physiological Population Regulation Role S Phase Specificity Stress Testing Time Toxic effect Work adenine analog cancer cell cell killing cell type chemical genetics chemotherapy cyclin-dependent kinase-activating kinase falls flexibility gain of function gene product genetic analysis genetic approach genome integrity inhibitor/antagonist insight knockout gene novel strategies premature prevent repaired response scaffold small molecule small molecule inhibitor tumor

项目摘要

DESCRIPTION (provided by applicant): Proper regulation of cell division is required for normal growth, development and genomic integrity; aspects of this control are lost or disrupted in human cancers. The cyclin-dependent kinases (CDKs) drive all major transitions in the cell division cycle. Mammalian cells have multiple downstream effector CDKs but, as we show, a single upstream CDK-activating kinase (CAK), Cdk7. Gene knockout and silencing studies suggested redundancy in the CDK network, by showing that Cdk2-long thought to be the principal driver of DNA synthesis (S) phase-was dispensable for viability. However, our work-using a chemical-genetic approach that selectively inactivates catalytic function of the targeted CDK while sparing non-catalytic, "scaffold" functions-uncovered strict requirements for Cdk2 activity in proliferation of both transformed and non- transformed human cells. An important function of Cdk2 is to prevent premature activation of Cdk1, and thereby ensure coordinated progression through S phase. That function depends on a kinetically more favorable pathway for activation of Cdk2, compared to Cdk1, due in part to different mechanisms of recognition by Cdk7. I hypothesize that specialized functions of Cdk2-in regulating gene expression, coordinating S phase and responding to DNA damage or replication stress-emerge from its unique mode of activation. I propose, moreover, that another distinct pathway by which Cdk7 activates Cdk4 and Cdk6-which function prior to cell-cycle commitment-is directly or indirectly coupled to mitogen-sensing pathways. The specific aims are: 1. To dissect the G1/S regulatory network comprising Cdk7, Cdk2, Cdk4 and Cdk6 2. To probe specific functions of Cdk7 and Cdk2 in the DNA damage response 3. To target the Cdk2 activation pathway with small molecule inhibitors Our preliminary studies reveal a unitary CAK-CDK network that achieves regulatory flexibility through kinetically distinct modes of kinase activation and inactivation. I ow propose to probe specific functions of CAK and the downstream CDKs in coordinating constitutive cell-cycle events and ensuring effective responses to genotoxic insults; and to test a new paradigm for inhibiting a specific CDK by selective targeting of its activation pathway. These studies promise to advance basic understanding of cell-cycle control, and to reveal novel strategies for anti-CDK therapy of human cancer.

描述（由申请人提供）：正常生长、发育和基因组完整性需要适当的细胞分裂调节；这种控制的某些方面在人类癌症中丢失或中断。细胞周期蛋白依赖性激酶（CDKs）驱动细胞分裂周期中的所有主要转变。哺乳动物细胞有多个下游效应cdk，但正如我们所展示的，只有一个上游cdk激活激酶（CAK）， Cdk7。基因敲除和沉默研究表明，CDK网络中存在冗余，表明长期以来被认为是DNA合成(S)阶段的主要驱动因素的cdk2对于生存能力是必不可少的。然而，我们的工作——使用一种化学遗传学方法，选择性地失活靶向CDK的催化功能，同时保留非催化的“支架”功能——揭示了Cdk2活性在转化和非转化人类细胞增殖中的严格要求。Cdk2的一个重要功能是防止Cdk1过早激活，从而确保通过S期的协调进展。与Cdk1相比，该功能依赖于Cdk2激活的动力学更有利的途径，部分原因是Cdk7的识别机制不同。我推测cdk2在调节基因表达、协调S期和应对DNA损伤或复制应激方面的特殊功能来自其独特的激活模式。此外，我提出，Cdk7激活Cdk4和cdk6的另一种不同途径直接或间接地与丝裂原感应途径耦合，而cdk6在细胞周期承诺之前起作用。具体目标是：1。剖析G1/S调控网络，包括Cdk7、Cdk2、Cdk4和Cdk6 2。探讨Cdk7和Cdk2在DNA损伤应答中的具体功能。我们的初步研究揭示了一个统一的CAK-CDK网络，通过动力学上不同的激酶激活和失活模式实现调控灵活性。我现在提议探索CAK和下游CDKs在协调构成细胞周期事件和确保对遗传毒性损伤的有效反应中的特定功能；为了测试a